open access
Simultaneous detection of tumor cells and the positive result of genetic test for Mycobacterium tuberculosis in pleural effusion
open access
Abstract
Pneumonol. Alergol. Pol. 2010; 78, 4: 296-301
Abstract
Pneumonol. Alergol. Pol. 2010; 78, 4: 296-301
Keywords
pleural tuberculosis; cancer of unknown primary site; immunohistochemical examination


Title
Simultaneous detection of tumor cells and the positive result of genetic test for Mycobacterium tuberculosis in pleural effusion
Journal
Advances in Respiratory Medicine
Issue
Article type
Case report
Pages
296-301
Published online
2010-07-08
Bibliographic record
Pneumonol Alergol Pol 2010;78(4):296-301.
Keywords
pleural tuberculosis
cancer of unknown primary site
immunohistochemical examination
Authors
Monika Czystowska
Anna Stokłosa
Ewa Szczepulska-Wójcik
Krystyna Maszkowska-Kopij
Lucyna Opoka
Agnieszka Skoczylas
Dorota Górecka


- Grzelewska-Rzymowska I. Gruźlica i inne mykobakteriozy. In: Szczeklik A. ed. Choroby wewnętrzne. . Med. Prakt., Kraków 2005: 591–602.
- Korzeniewska-Koseła M. Gruźlica i choroby układu oddechowego w Polsce w 2008 roku. Instytut Gruźlicy i Chorób Płuc, Warszawa 2009.
- Schaaf HS, Zumla A. Tuberculosis. A comprehensive clinical reference. Saunders Elsevier Ltd, Oxford 2009.
- Remiszewski P, Słodkowska J, Wiatr E, et al. Fatal infection in patients treated for small cell lung cancer in the Institute of Tuberculosis and Chest Diseases in the years 1980-1994. Lung Cancer. 2001; 31(2-3): 101–110.
- de Wit D, Maartens G, Steyn L. A comparative study of the polymerase chain reaction and conventional procedures for the diagnosis of tuberculous pleural effusion. Tuber Lung Dis. 1992; 73(5): 262–267.
- Beige J, Lokies J, Schaberg T, et al. Clinical evaluation of a Mycobacterium tuberculosis PCR assay. J Clin Microbiol. 1995; 33(1): 90–95.
- Varadhachary GR. Carcinoma of unknown primary origin. Gastrointest Cancer Res. 2007; 1(6): 229–235.
- Briasoulis E, Pavlidis N, Felip E, et al. ESMO Guidelines Working Group. Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20 Suppl 4: 154–155.
- Bugat R, Bataillard A, Lesimple T, et al. FNCLCC. Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer. 2003; 89 Suppl 1: S59–S66.
- Krzemieniecki K. Ogólne zasady diagnostyki nowotworów. In: Szczeklik A. ed. Choroby wewnętrzne. . Med. Prakt., Kraków 2005: 1993–1996.
- McMillan JH, Levine E, Stephens RH. Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site. A retrospective study. Radiology. 1982; 143(1): 143–146.
- Abbruzzese JL, Abbruzzese MC, Lenzi R, et al. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995; 13(8): 2094–2103.
- Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer. 2004; 101(11): 2641–2649.
- Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004; 100(9): 1776–1785.
- Olson JA, Morris EA, Van Zee KJ, et al. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol. 2000; 7(6): 411–415.
- Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem. 2002; 48(8): 1151–1159.
- Sheth SS. Elevated CA 125 in advanced abdominal or pelvic tuberculosis. Int J Gynaecol Obstet. 1996; 52(2): 167–171.
- Giovanella L, Ceriani L, Giardina G, et al. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Clin Chem Lab Med. 2002; 40(3): 298–303.
- Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol. 1996; 9(4): 445–452.
- Tan D, Li Q, Deeb G, et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol. 2003; 34(6): 597–604.
- Chen H, Brahmer J. Management of malignant pleural effusion. Curr Oncol Rep. 2008; 10(4): 287–293.
- Neragi-Miandoab S. Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer. 2006; 54(1): 1–9.